Vivos Therapeutics Inc Stock Price, News & Analysis

Vivos Therapeutics (NASDAQ: VVOS) announced the publication of groundbreaking clinical trial results in the European Journal of Pediatrics, demonstrating the effectiveness of their Daytime-Nighttime Appliance (DNA) in treating pediatric obstructive sleep apnea (OSA). The study showed 79% of patients experienced OSA improvement, with 61.7% improving by 50% or more.

The trial results validate Vivos' FDA 510(k) clearance received in September 2024 for treating moderate to severe OSA in children. Notably, 93% of children with severe OSA saw symptoms decrease by at least 50%. The DNA device presents a non-surgical alternative to adenotonsillectomy, which has a 68% symptom relapse rate within three years.

Vivos Therapeutics (NASDAQ: VVOS) has completed the acquisition of The Sleep Center of Nevada (SCN), marking a significant pivot in its business model. The $6M cash and $1.5M stock deal includes potential additional $1.5M in stock based on performance milestones. SCN, Nevada's largest sleep testing center, sees 3,000 new patients monthly and generates high seven-figure annual revenues. The acquisition was financed through an $8.225M secured loan from Streeterville Capital and a $3.755M private placement from New Seneca Partners. This strategic move shifts Vivos from a dental provider network model to directly managing sleep practices, allowing immediate capture of OSA diagnostic revenue and treatment opportunities. SCN's network of seven locations and 50 beds for sleep testing, led by Dr. Prabhu Rachakonda and Dr. Tara Rachakonda, will now offer Vivos' FDA-cleared OSA treatments to patients, with full integration expected over 12-18 months.

Vivos Therapeutics (NASDAQ: VVOS) reported its Q1 2025 financial results, showing mixed performance as the company transitions to a new business model. Total revenue decreased to $3.0 million from $3.4 million in Q1 2024, though product revenue increased 8% year-over-year. The company reported a net loss of $3.9 million, slightly higher than the $3.8 million loss in Q1 2024. Operating expenses decreased 5% to $5.4 million, reflecting cost-cutting measures. Notably, Vivos announced plans to acquire The Sleep Center of Nevada for up to $9 million, marking a strategic shift towards direct patient access. The company sold 3,736 oral appliance arches in Q1 2025, generating approximately $1.8 million in revenue. Implementation of new CPT® medical codes for CARE oral medical devices aims to improve reimbursement processes.

Vivos Therapeutics (NASDAQ: VVOS), a medical device and technology company focused on sleep-related breathing disorders treatments, has scheduled its first quarter 2025 financial results release for May 15, 2025, after market close. The company will host a conference call at 5:00 PM ET on the same day to discuss results and recent developments.

Investors can join via phone at (800) 717-1738 (US) or (646) 307-1865 (International). A replay will be available until May 29, 2025, accessible at (844) 512-2921 (US) or (412) 317-6671 (International) with passcode 1124460. A live webcast will be available on Vivos' website with 30-day replay access.

Vivos Therapeutics (NASDAQ: VVOS) has signed a definitive agreement to acquire The Sleep Center of Nevada (SCN), the largest sleep center operator in Nevada, for up to $9 million. The deal includes $6 million in cash, $1.5 million in Vivos common stock at closing, and potential additional $1.5 million in stock tied to performance milestones.

SCN, founded in 2008, serves approximately 3,000 new patients monthly and has generated high seven-figure annual net revenues. The center operates seven locations with nearly 50 beds for overnight sleep testing. About 90% of SCN patients test positive for OSA, with 95% typically referred for CPAP, traditional oral devices, or surgical options.

The acquisition, expected to close in Q2 or Q3 2025, aligns with Vivos' new marketing and distribution model following its June 2024 alliance with Rebis Health. The company aims to expand its FDA-cleared oral appliance treatments for OSA directly to patients seeking alternatives to CPAP or surgery.

Vivos Therapeutics (NASDAQ: VVOS) reported strong financial results for full year 2024, with revenue increasing 9% to $15.0 million from $13.8 million in 2023. Product revenue grew 26% year-over-year, while operating expenses decreased 21% to $20.2 million.

The company maintained a 60% gross margin, with gross profit reaching $9.0 million. Operating loss decreased significantly by 35% to $11.2 million. Cash position stood at $6.3 million after raising $17.9 million through equity transactions in 2024.

Notable achievements include FDA 510(k) clearance for the DNA appliance to treat moderate to severe OSA in children ages 6-17, complementing their 2023 clearance for adult treatment. Patient treatments increased to 58,000 worldwide, up from 42,000 in 2023. The company implemented a strategic pivot towards contractual, profit-sharing alliances with sleep healthcare providers, starting with Rebis Health Holdings, expecting to increase revenue per case by 4-6 times with 50% contribution margins.

Vivos Therapeutics (NASDAQ: VVOS), a medical device and technology company focused on sleep-related breathing disorders treatments, has scheduled its full year 2024 financial results release for Monday, March 31, 2025, after market close.

The company will host a conference call at 5:00 PM ET on the same day to discuss the results and provide updates on recent milestones. Investors can join via phone at (800) 717-1738 (US) or (646) 307-1865 (International). A replay will be available until April 14, 2025, using passcode 1103883. The webcast can be accessed through Vivos' investor relations website, with a 30-day archive available.

Vivos Therapeutics (NASDAQ: VVOS) announced significant expansions and achievements in its strategic alliance with Rebis Health Holdings. The company is extending its FDA-cleared Vivos CARE treatment for OSA into two additional Denver market facilities and plans nationwide expansion through sleep center affiliations and acquisitions.

Initial data shows a 64% acceptance rate for Vivos treatment, with patients preferring it nearly 2:1 over CPAP. The company reports average per case revenue of over $4,700 with gross margins around 70% before profit sharing with Rebis. The new business model shows potential for up to four times greater profit per case compared to their previous distribution model.

The expansion includes new locations in Highlands Ranch and Westminster, expected to be operational by April. Vivos is exploring partnerships with over 2,500 accredited sleep medicine groups nationwide, aiming to accelerate revenue growth and achieve cash flow-positive operations.

Vivos Therapeutics (NASDAQ: VVOS), a medical device and technology company focused on sleep-related breathing disorders, has announced a fireside chat scheduled for February 18, 2025, at 12:00 pm ET. CEO Kirk Huntsman will engage with Water Tower Research's senior analyst Do Kim to discuss several key topics.

The discussion will cover the company's Vivos CARE devices for treating obstructive sleep apnea (OSA) and snoring in adults, as well as moderate to severe OSA in children aged 6-17. Key points to be addressed include the company's strategic shift to a medical-based business model, efforts to establish partnerships with physician-based sleep groups, OSA market dynamics, and the positioning of Vivos CARE devices in OSA treatment.

The event will be listen-only, with a replay available for 30 days in the Investor Relations section of the Vivos website.